Derek Zukosky
Urology · Golden, CONPI 1912942038
Payments from drug & device makers
What this record shows
This record is dominated by education: $396,759 of the $442,293 with a category attached, or 89.7%. Intuitive Surgical accounts for 98.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $84,056 and has fallen 52.2% since, to $40,191 in 2025. Among urology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $972.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$434K
- Boston Scientific$2K
- Procept Biorobotics Corporation$2K
- Axonics, Inc.$2K
- Coloplast$1K
- Palette Life Sciences, Inc.$646
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$21,4005%
- Travel & lodging$4,6431%
- Food & beverage$19,4904%
- Education$396,75990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 305 | $433,824 |
| Boston Scientific | 31 | $2,276 |
| Procept Biorobotics Corporation | 9 | $1,772 |
| Axonics, Inc. | 34 | $1,516 |
| Coloplast | 20 | $1,011 |
| Palette Life Sciences, Inc. | 3 | $646 |
| Astellas Pharma US Inc | 15 | $252 |
| Bayer | 3 | $210 |
| Calyxo, Inc. | 1 | $121 |
| AbbVie(2 entities) | 7 | $110 |
| Rochester Medical Corporation | 3 | $66 |
| Olympus Corporation Of The Americas | 1 | $65 |
| Antares Pharma, Inc. | 4 | $63 |
| Dendreon Pharmaceuticals LLC | 2 | $54 |
| Pfizer | 3 | $51 |
| Novartis | 2 | $45 |
| Amgen | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Bioprotect Medical, Inc. | 1 | $29 |
| 180 Medical, Inc. | 1 | $19 |
| Agiliti Surgical, Inc. | 1 | $19 |
| RGH Enterprises LLC | 1 | $18 |
| Myovant Sciences Inc. | 1 | $18 |
| Dentsply IH Inc. | 1 | $14 |
| Blue Earth Diagnostics | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$425,478
- DA VINCI SP$7,800
- AquaBeam Robotic System$1,571
- AMS$1,313
- Bulkamid$641
- Axonics$641
- ALTIS$364
- Solyx SIS System$134
- CVAC Aspiration System$121
- GENERAL ERECTILE DYSFUNCTION$119
- TITAN$118
- Nubeqa$103
- Xofigo$103
- GENERAL ONCOLOGY$101
How this compares
$442,293 in reported general payments places this provider in the 95th percentile of 225 urology providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 22 | $299,048 |
| MyrbetriqMirabegron | 98 | $48,651 |
| GemtesaVibegron | 57 | $39,839 |
| VeozahFezolinetant | 11 | $5,950 |
| Tamsulosin Hcl | 439 | $4,299 |
| Solifenacin Succinate | 79 | $1,470 |
| Finasteride | 127 | $1,363 |
| Cephalexin | 171 | $1,152 |
| Potassium Citrate ErPotassium Citrate | 23 | $1,115 |
| Estradiol | 16 | $1,101 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 32 | $818 |
| Doxazosin Mesylate | 11 | $308 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $307 |
| Ciprofloxacin Hcl | 46 | $226 |
| Oxybutynin Chloride | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq, Veozah | $252 | $353,648131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 urology providers in Colorado.
Other urology in Golden
- David CahnGolden$58K
- Thomas FacelleGolden$7K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.